Kar Therapeutics & Estates Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 29.98 Cr
as on 12-12-2024
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 83.80%
(FY 2021)
- Profit 32.91%
(FY 2021)
- Ebitda 26.59%
(FY 2021)
- Net Worth -8.51%
(FY 2021)
- Total Assets -0.89%
(FY 2021)
About Kar Therapeutics & Estates
The Corporate was formerly known as Dr.Reddy's Estates Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 29.98 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Kar Therapeutics & Estates Private Limited India is Preksha Fulfagar as COMPANY SECRETARY. Satish Kallam and Kallam Reddy serve as directors at the Company.
- CIN/LLPIN
U24233TG1995PTC020683
- Company No.
020683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationHyderabad., Telangana
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kar Therapeutics & Estates?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Preksha Fulfagar | Company Secretary | 01-Jun-2019 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Kallam  | Director | 14-Jun-1995 | Current |
| Kallam Reddy | Director | 28-Jul-1995 | Current |
Financial Performance and Corporate Structure Insights of Kar Therapeutics & Estates.
Kar Therapeutics & Estates Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 83.8% increase. The company also saw a substantial improvement in profitability, with a 32.91% increase in profit. The company's net worth dipped by a decrease of 8.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kar Therapeutics & Estates?
In 2020, Kar Therapeutics & Estates had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kar Therapeutics & Estates?
Unlock and access historical data on people associated with Kar Therapeutics & Estates, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kar Therapeutics & Estates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kar Therapeutics & Estates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
